Swiss National Bank boosted its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 2.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 63,900 shares of the medical instruments supplier’s stock after purchasing an additional 1,500 shares during the period. Swiss National Bank’s holdings in STAAR Surgical were worth $2,247,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of STAA. Defender Capital LLC. increased its holdings in STAAR Surgical by 3.1% in the 4th quarter. Defender Capital LLC. now owns 602,453 shares of the medical instruments supplier’s stock worth $21,188,000 after acquiring an additional 18,225 shares in the last quarter. Jericho Capital Asset Management L.P. acquired a new position in shares of STAAR Surgical during the 3rd quarter worth $5,413,000. California Public Employees Retirement System raised its stake in shares of STAAR Surgical by 13.8% during the 4th quarter. California Public Employees Retirement System now owns 95,600 shares of the medical instruments supplier’s stock worth $3,362,000 after buying an additional 11,600 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of STAAR Surgical during the 3rd quarter worth $1,949,000. Finally, Rhumbline Advisers raised its stake in shares of STAAR Surgical by 2.8% during the 4th quarter. Rhumbline Advisers now owns 75,326 shares of the medical instruments supplier’s stock worth $2,649,000 after buying an additional 2,077 shares during the last quarter. Hedge funds and other institutional investors own 96.76% of the company’s stock.
STAAR Surgical stock traded up $0.46 during midday trading on Wednesday, reaching $31.83. 2,945 shares of the company were exchanged, compared to its average volume of 531,142. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 106.10 and a beta of 2.07. The firm’s 50-day simple moving average is $36.29 and its 200-day simple moving average is $33.27. STAAR Surgical has a 1 year low of $21.70 and a 1 year high of $42.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.57 and a current ratio of 5.07.
STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, February 26th. The medical instruments supplier reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.09. The firm had revenue of $38.88 million during the quarter, compared to analysts’ expectations of $39.10 million. STAAR Surgical had a return on equity of 14.71% and a net margin of 9.35%. During the same quarter last year, the business posted $0.02 EPS. On average, analysts forecast that STAAR Surgical will post 0.48 EPS for the current fiscal year.
Several research firms have recently issued reports on STAA. ValuEngine raised STAAR Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, February 25th. Canaccord Genuity lifted their price target on STAAR Surgical from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Stephens reaffirmed a “buy” rating and set a $56.00 price target on shares of STAAR Surgical in a research note on Thursday, January 2nd. BidaskClub downgraded STAAR Surgical from a “sell” rating to a “strong sell” rating in a research note on Friday, February 28th. Finally, BTIG Research began coverage on STAAR Surgical in a research note on Wednesday, December 4th. They set a “buy” rating and a $46.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. STAAR Surgical presently has a consensus rating of “Buy” and a consensus target price of $44.25.
In related news, CFO Deborah J. Andrews sold 106,604 shares of STAAR Surgical stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $42.20, for a total transaction of $4,498,688.80. Following the completion of the sale, the chief financial officer now owns 52,101 shares in the company, valued at approximately $2,198,662.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jon K. Hayashida sold 47,408 shares of STAAR Surgical stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $37.20, for a total value of $1,763,577.60. Following the sale, the vice president now owns 53,658 shares of the company’s stock, valued at approximately $1,996,077.60. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
See Also: Trading based on a resistance level
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.